Clinical Trials Logo

Filter by:
NCT ID: NCT06460545 Not yet recruiting - Hepatitis A Clinical Trials

Phase IV Study of Concomitant Administration of the sIPV and HepA

Start date: June 15, 2024
Phase: Phase 4
Study type: Interventional

This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and HepA-L or HepA-I in children aged 18 months. The primary immunogenicity endpoints in all groups are the seroconversion rates of type I, II, and III anti-poliovirus neutralizing antibodies and the seroconversion rate of anti-hepatitis A virus antibodies 30 days after the final administration. The secondary immunogenicity endpoints are (1) the GMT/GMC of type I, II, and III anti-poliovirus neutralizing antibodies as well as the anti-hepatitis A virus antibodies 30 days after the final administration; (2) the seropositive rates of the anti-hepatitis A virus antibodies 30 days after the final administration; (3) the GMFI of type I, II, and III anti-poliovirus neutralizing antibodies as well as the anti-hepatitis A virus antibodies 30 days after the final administration. The secondary safety endpoints are the incidence of adverse events (AEs) within 30 minutes after each injection, the incidence of solicited local and systematic AEs in the period of solicitation after each injection, the incidence of unsolicited AEs in 30 days after each injection, the incidence of AEs in 30 days after each injection, and the incidence of serious adverse events in 6 months after administrations.

NCT ID: NCT06459973 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

Start date: July 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

NCT ID: NCT06459427 Not yet recruiting - Clinical trials for Robotic Surgical Procedures

Robot-Assisted Minimally Invasive Surgery for Brainstem Hemorrhage

Start date: July 2025
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to observe the improvements in clinical symptoms and imaging outcomes for brainstem hemorrhage using robot-assisted stereotactic puncture, evaluate the clinical efficacy and safety of this treatment, and explore the development of a high-precision, intelligent, and individualized microsurgical diagnosis and treatment process for brainstem hemorrhage. The main questions it aims to address are: - Establish a multi-center clinical database for brainstem hemorrhage. - Clinically observe and evaluate the intervention effects of robot-assisted stereotactic puncture on brainstem hemorrhage, compare it with the traditional conservative treatment control group, and investigate its efficacy and impact on patient survival, motor evoked potentials, and the degree of neurological deficits. - Optimize the Artificial Intelligence (AI) algorithm-based robotic surgical assistance system, and explore the prediction of preoperative brainstem hematoma stability and hematoma path planning. Participants in the experimental group will: - Undergo robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture - Receive conservative non-surgical treatment. If there is a control group: the researchers will compare the conservative non-surgical treatment group to evaluate the effectiveness of robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture.

NCT ID: NCT06459310 Not yet recruiting - Aging Clinical Trials

Pilot Study on Evaluating the Geroprotective Effect of Metformin

AGE-M
Start date: June 30, 2024
Phase: Phase 2
Study type: Interventional

The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.

NCT ID: NCT06459167 Not yet recruiting - Emergencies Clinical Trials

Position Intervention to Reduce Hypoxemia in Sedation Patients

Start date: June 20, 2024
Phase: N/A
Study type: Interventional

Hypoxemia was defined as an SpO2 of < 90% for any duration. Failure to treat promptly can lead to hypoxemia, which may increase the risks of arrhythmia, nausea and vomiting, and cognitive dysfunction. Studies have shown that body position has a direct impact on respiratory function. In special environments, including outside the operating room where emergency airway management for critically ill and injured patients is needed, or in areas with limited medical resources like remote areas, adopting simple interventions by changing position to maintain patients' respiratory function can be more economical, convenient and safe.

NCT ID: NCT06458595 Not yet recruiting - Clinical trials for Age-related Macular Degeneration

Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Start date: June 28, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.

NCT ID: NCT06458257 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

Start date: June 2024
Phase:
Study type: Observational

For newly diagnosed high-relapse-risk CEBPA mutant acute myeloid leukemia patients, we aim to perform allogeneic hematopoietic stem cell transplantation after patients finished one cycle of induction and two cycles of consolidation. To access whether the therapeutic regimen is effective for high-relapse-risk CEBPA mutant acute myeloid leukemia, the disease-free-survival (DFS), overall survival (OS), non-relapse-mortality of patients is evaluated.

NCT ID: NCT06458244 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

The Efficacy of Allo-HSCT in ND HR-CBF-AML

Start date: June 2024
Phase:
Study type: Observational

For newly diagnosed high-relapse-risk core-binding-factor acute myeloid leukemia participants, the investigators aim to perform allogeneic hematopoietic stem cell transplantation after participants finished one cycle of induction and two cycles of consolidation. To access whether the therapeutic regimen is effective for high-relapse-risk core-binding-factor acute myeloid leukemia, the disease-free-survival (DFS), overall survival (OS), non-relapse-mortality of participants is evaluated.

NCT ID: NCT06458101 Not yet recruiting - Urolithiasis Clinical Trials

Efficacy and Safety of Ureteroscopic Lithotripsy (Including Flexible Ureteroscopy) Without Indwelling Urinary Catheter

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

A prospective, multicenter, randomized, controlled clinical trial was conducted to compare the efficacy and safety of non-indwelling catheter and indwelling catheter in relieving postoperative catheter-related complications after ureteroscopic lithotripsy. By comparing the pain score and urination urgency score (PPIUS) of patients after ureteroscopic lithotripsy (including flexible ureteroscopy) lithotripsy to provide a reliable scientific basis for indwelling catheter after ureteroscopic lithotripsy.

NCT ID: NCT06457984 Not yet recruiting - Type 2 Diabetes Clinical Trials

Effects of Selenium Towards Type 2 Diabetes

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

According to the prevalence of non-communicable chronic diseases and aging population characteristics, this study is exploring the coexist effects combined with various dimensions: nutritional functions, metabolic homeostasis, inflammation and immunity by the selenium supplementation among type 2 diabetes, which based on insulin resistance, beta-cell function disorders, and body metabolic homeostasis disorders of the mechanism of type 2 diabetes by lifecycle so that could provide with a totally new and safe nutritional method for type 2 diabetes prevention and diagnosis.